All Stories

  1. Logics of (dis)engagement: mapping variation in non-government norms and approaches to alcohol, ultra-processed food and related industries - a case study from Australia
  2. Monitoring privilege for health equity: building consensus on indicators to monitor socioeconomic advantage through a modified Delphi survey
  3. Doing (and undoing) privilege: evaluating how public policy drives health inequities
  4. Protecting Access to Medicines After Cambodia Graduates From Least Developed Country Status: A Policy Analysis
  5. Pandemic Agreement Must Include Levers to Redirect Pharmaceutical Industry Behaviour During Pandemics Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap"
  6. Factors influencing the prioritisation of access to medicines in trade‐related intellectual property policymaking in Thailand
  7. Trade and investment
  8. NGOs and Global Business Regulation of Transnational Alcohol and Ultra-Processed Food Industries
  9. A framework of NGO inside and outside strategies in the commercial determinants of health: findings from a narrative review
  10. Global inequities in access to COVID-19 health products and technologies: A political economy analysis
  11. Public health advocacy strategies to influence policy agendas: lessons from a narrative review of success in trade policy
  12. Advancing Indigenous self-determination and health equity: Lessons from a failed Australian public policy
  13. Why are Indigenous Affairs Policies Framed in ways that Undermine Indigenous Health and Equity?
  14. Four actions Australia should take to advance equitable global access to COVID‐19 vaccines
  15. Governing ultra‐processed food and alcohol industries: the presence and role of non‐government organisations in Australia
  16. What is the impact of intellectual property rules on access to medicines? A systematic review
  17. Promoting action on structural drivers of health inequity: principles for policy evaluation
  18. Power and the people's health
  19. Defending access to medicines in regional trade agreements: lessons from the Regional Comprehensive Economic Partnership – a qualitative study of policy actors’ views
  20. Australia in 2030: what is our path to health for all?
  21. Universal health coverage for the poorest billion: justice and equity considerations
  22. Glossary on free trade agreements and health part 2: new trade rules and new urgencies in the context of COVID-19
  23. Glossary on free trade agreements and health part 1: the shift from multilateralism and the rise of ‘WTO-Plus’ provisions
  24. International Trade Agreements and Global Health: Pathways and Politics
  25. Creating Political Will for Action on Health Equity: Practical Lessons for Public Health Policy Actors
  26. Industry submissions on alcohol in the context of Australia's trade and investment agreements: A content and thematic analysis of publicly available documents
  27. Advancing a health equity agenda across multiple policy domains: a qualitative policy analysis of social, trade and welfare policy
  28. International Trade and Investment and Food Systems: What We Know, What We Don’t Know, and What We Don’t Know We Don’t Know
  29. Tackling NCDs: The Need to Address Alcohol Industry Interference and Policy Incoherence Across Sectors Comment on "Towards Preventing and Managing Conflict of Interest in Nutrition Policy? An Analysis of Submissions to a Consultation on a Draft WHO Tool"
  30. What Generates Attention to Health in Trade PolicyMaking? Lessons From Success in Tobacco Control and Access to Medicines: A Qualitative Study of Australia and the (Comprehensive and Progressive) Trans-Pacific Partnership
  31. Trade and investment agreements as structural drivers for NCDs: the new public health frontier
  32. Bringing in critical frameworks to investigate agenda-setting for the social determinants of health: Lessons from a multiple framework analysis
  33. A glossary of theories for understanding power and policy for health equity
  34. The nexus between international trade, food systems, malnutrition and climate change
  35. International Trade Agreements and Global Health: Pathways and Politics
  36. Next Steps for Elevating Health on Trade and Investment Policy Agendas Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention"
  37. Toxic trade: the impact of preferential trade agreements on alcohol imports from Australia in partner countries
  38. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts
  39. Public health over private wealth: rebalancing public and private interests in international trade and investment agreements
  40. How can multiple frames enable action on social determinants? Lessons from Australia’s paid parental leave
  41. How do actors with asymmetrical power assert authority in policy agenda-setting? A study of authority claims by health actors in trade policy
  42. An exposé of the realpolitik of trade negotiations: implications for population nutrition
  43. How does policy framing enable or constrain inclusion of social determinants of health and health equity on trade policy agendas?
  44. Power asymmetries, policy incoherence and noncommunicable disease control - a qualitative study of policy actor views
  45. Japan's emerging role in the global pharmaceutical intellectual property regime: A tale of two trade agreements
  46. Financial costs associated with monopolies on biologic medicines in Australia
  47. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines
  48. Pharma's next frontier? New threats to public health in the Regional Comprehensive Economic Partnership agreement
  49. International medicines governance 1940s to 1970s: lessons for public health
  50. Emerging theoretical frameworks for global health governance
  51. Global Health Governance: Framework Convention on Tobacco Control (FCTC), the Doha Declaration, and Democratisation
  52. Pharma's Next Frontier? New Threats to Public Health in the Regional Comprehensive Economic Partnership Agreement